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ABSTRACT:
The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin 
(mTOR) signaling axis plays a central role in cell proliferation, growth, and survival 
under physiological conditions. However, aberrant PI3K/Akt/mTOR signaling has been 
implicated in many human cancers, including acute myelogenous leukemia (AML). 
Therefore, the PI3K/Akt/mTOR network is considered as a validated target for innovative 
cancer therapy. The limit of acceptable toxicity for standard polychemotherapy has 
been reached in AML. Novel therapeutic strategies are therefore needed. This review 
highlights how the PI3K/Akt/mTOR signaling axis is constitutively active in AML 
patients, where it affects survival, proliferation, and drug-resistance of leukemic cells 
including leukemic stem cells. Effective targeting of this pathway with small molecule 
kinase inhibitors, employed alone or in combination with other drugs, could result in 
the suppression of leukemic cell growth. Furthermore, targeting the PI3K/Akt/mTOR 
signaling network with small pharmacological inhibitors, employed either alone or in 
combinations with other drugs, may result in less toxic and more efficacious treatment 
of AML patients. Efforts to exploit pharmacological inhibitors of the PI3K/Akt/mTOR 
cascade which show efficacy and safety in the clinical setting are now underway.
INTRODUCTION
Acute myelogenous leukemia (AML) is a highly het-
erogeneous group of malignant clonal diseases character-
ized by deregulated proliferation of hematopoietic stem 
cells and myeloid progenitors. This results in accumula-
tion, in the bone marrow, of myeloid cells with an impaired 
differentiation program and resistant to cell death. AML 
accounts for about 80% of adult leukemias and is a dis-
order of the elderly, with a median age at diagnosis of 65 
years and a growing incidence over 65 years [1]. Most 
AML cases respond well to initial polychemotherapy, but 
disease relapse occurs in the large majority of patients. The 
standard therapeutic approach for AML patients is high-
dose polychemotherapy, consisting of cytarabine and an 
anthracycline antibiotic like daunorubicin or idarubicin, 
or the anthracendione mitoxantrone [2]. While results of 
AML treatment have improved in younger patients who 
can tolerate intensified treatment strategies, there have 
been limited changes in outcome among individuals who 
are older than 60 years. Therefore, the prognosis of AML 
remains severe, with an overall 5-year survival rate around 
20%, despite continuous advances in our understanding 
of AML biology. Furthermore, patients with AML arising 
out of myelodysplastic syndrome or who are older than 60 
years have an even worse prognosis (<10% survival at 5 
years) [3]. Therefore, there remains a need for innovative, 
rationally designed, minimally toxic, therapies for AML, 
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especially for the elderly [4]. 
Only one subtype of AML, acute promyelocytic leuke-
mia (APL), displays a much better prognosis, as differenti-
ation therapy with arsenic trioxide or all-trans retinoic acid 
(ATRA), used alone or in combination with chemothera-
peutic drugs, has proven quite successful in APL patients 
[5]. It is now clear that a hierarchical organization of the 
hematopoietic system does exist in AML, as in normal 
hematopoiesis. Indeed, AML is initiated and maintained by 
a small, self-renewing population of leukemic stem cells 
(LSCs), which give rise to a progeny of more mature and 
highly cycling progenitors (colony forming unit-leukemia, 
CFU-L). CFU-Ls do not self-renew, however they are com-
mitted to proliferation and limited differentiation. By doing 
so, they originate a population of blast cells which consti-
tute the majority of leukemic cells in both the bone marrow 
and peripheral blood of patients. The exact phenotype of 
LSCs is still debated, but they are comprised in the CD34+/
CD38-/low population [6]. The majority of LSCs are quies-
cent and insensitive to traditional chemotherapeutic drugs. 
This latter feature explains, at least in part, the difficulties 
in eradicating this cell population by conventional poly-
chemotherapy. Thus, novel therapeutic strategies for AML 
eradication should also target LSCs [7]. In AML, aberrant 
activation of several signal transduction pathways strongly 
enhances the proliferation and survival of both LSCs and 
CFU-Ls [8, 9]. Therefore, these signaling networks are 
attractive targets for the development of innovative thera-
peutic strategies in AML [10].
The phosphatidylinositol 3-kinase (PI3K, a family of 
lipid kinases)/Akt/mammalian target of rapamycin (mTOR) 
signaling cascade is crucial to many widely divergent 
physiological processes which include cell cycle progres-
sion, transcription, translation, differentiation, apoptosis, 
Fig. 1.  The PI3K/Akt/mTOR signaling pathway. GPCRs, RTKs, and Ras activate PI3K. PI3K generates PtdIns (3,4,5)P3 from PtdIns (4,5)
P2. PtdIns (3,4,5)P3 attracts to the plasma membrane PDK1 which phosphorylates Akt on Thr308. Full Akt activation requires Ser473 phos-
phorylation which is effected by mTORC2. Most of the Akt substrates are inactivated by phosphorylation. Active Akt inhibits TSC2 activity 
through direct phosphorylation. TSC2 is a GAP that functions in association with TSC1 to inactivate the small G protein Rheb. Akt-driven 
TSC1/TSC2 complex inactivation allows Rheb to accumulate in a GTP-bound state. Rheb-GTP then activates the protein kinase activity 
of mTORC1. mTORC1 targets p70S6K and 4E-BP1 which are critical for translation. 4E-BP1 phosphorylation by mTORC1 results in the 
release of eIF4E, while p70S6K phosphorylates ribosomal S6 protein. The TSC1/2 complex is required to activate also mTORC2. However, 
other signaling cascades impinge on mTORC1, including GSK3β, the Ras/Raf/MEK/ERK1/2/p90RSK pathway, and the LKB1/AMPK network 
which is sensitive to the ADP/ATP ratio. Arrows indicate activating events, whereas perpendicular lines indicate inhibitory events. 
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motility, and metabolism [11]. However, the PI3K/Akt/
mTOR signaling pathway represents one of the major sur-
vival pathways that is deregulated in many human cancers 
and contributes to both cancer pathogenesis and therapy 
resistance. Over the last few years, it has been reported 
that constitutive activation of the PI3K/Akt/mTOR signal-
ing network is a common feature of AML patients [12]. 
Furthermore, pathway activation confers leukemogenic 
potential to mouse hematopoietic cells [13]. Therefore, this 
signal transduction cascade may represent a valuable target 
for innovative therapeutic treatment of AML patients. The 
aim of this review is to give the reader an updated overview 
of the relevance of PI3K/Akt/mTOR signaling activation in 
AML patients and to focus on small molecules which will 
possibly have an impact on the therapeutic arsenal we have 
against this disease. 
The PI3K/Akt/mTOR pathway
PI3K
The family of PI3K enzymes is characterized by the 
ability to phosphorylate the 3’-OH group in inositol lipids 
and comprises three different classes, I, II, and III. Class 
I PI3K preferred substrate is phosphatidylinositol 4,5 
bisphosphate [PtdIns (4,5)P2] which is phosphorylated to 
phosphatidylinositol 3,4,5 trisphosphate [PtdIns (3,4,5)P3] 
[14, 15]. PtdIns (3,4,5)P3 recruits to the plasma membrane 
pleckstrin homology (PH) domain-containing proteins, 
which include phosphoinositide-dependent protein kinase 
1 (PDK1) and Akt. Class I PI3K is divided further into A 
[activated by receptor tyrosine kinases (RTKs), Ras, and 
G-protein coupled receptors (GPCRs)] and B (activated by 
GPCRs) subtype (Figure 1). Class IA PI3Ks are heterodi-
meric enzymes composed of a regulatory (p85α, p85β, 
p55α, p55γ, p50α) and of catalytic (p110α, p110β, p110δ) 
subunits. Class IB PI3K comprises a p101 regulatory and a 
p110γ catalytic subunit [16]. Both p110α and p110β PI3K 
play fundamental roles during development, so that their 
homozygous knockout is embryonic-lethal [17]. In con-
trast, p110γ and p110δ PI3Ks are mostly related to the 
immune system functions, so that their knock-down leads 
to defective immune responses [18]. Class II PI3Ks, which 
comprise the PI3K-C2α, -C2β, and -C2γ isoforms, prefer-
entially phosphorylate phosphatidylinositol to yield phos-
phatidylinositol 3 phosphate. Although class II PI3Ks are 
widely expressed in mammalian organs and tissues, their 
relevance in cell signaling and cancer biology is not clear 
at the moment [19].
Vacuolar protein sorting 34 (vps34) is the only class III 
PI3K and exists as a heterodimer bound to the vps15 regu-
latory subunit (previously referred to as p150 in mammals). 
Vps34 has been implicated in nutrient signaling, endocyto-
sis, and autophagy [20].
Activating mutations in the gene coding for p110α 
(PIK3CA) have been found in many human cancer types, 
including tumors of the colon, brain, ovary, breast, liver, 
and stomach, and could at least partially explain pathway 
up-regulation in these neoplasms [21]. Nevertheless, in 
tumor models (brain, prostate, breast) driven by PTEN 
(phosphatase and tensin homolog deleted on chromosome 
10) deficiency, knock-out of p110β, but not p110α, was 
required to inhibit Akt activation [17]. Wild-type p110α is 
not oncogenetic when overexpressed, whereas wild-type 
p110β, p110γ, and p110δ PI3Ks are oncogenetic when 
ectopically expressed in chicken fibroblasts [22]. Neverthe-
less, their contribution to oncogenesis is only beginning to 
emerge [23].
Akt
Akt, a 57-kDa serine/threonine protein kinase, is the cel-
lular homolog of the v-akt oncogene. The Akt family com-
prises three highly conserved isoforms: Akt1/α, Akt2/β, and 
Akt3/γ, which display a high degree of sequence homology 
[14]. However, functional differences exist between Akt 
isoforms, as Akt2 is involved in insulin-mediated glucose 
uptake [24] and in cell motility/invasion/metastatic poten-
tial of cancer cells [25].
Akt contains an NH2-terminal PH domain, that interacts 
with PtdIns (3,4,5)P3. Once Akt is recruited at the plasma 
membrane, its activation loop is phosphorylated on Thr308 
by PDK1 while the mTOR complex 2 (mTORC2) phos-
phorylates Ser473 in the Akt COOH-terminus (Figure 1). 
Full Akt activation requires both the phosphorylation steps. 
Active Akt migrates to both the cytosol and the nucleus. 
Nuclear Akt may fulfil important anti-apoptotic roles [26]. 
Nevertheless, the relative contribution of Akt signaling at 
the plasma membrane, the cytosol, and the nucleus remains 
to be elucidated. However, it is intriguing that the protein 
promyelocytic leukemia (PML) is involved in the dephos-
phorylation of nuclear Akt as PML specifically recruits the 
Akt phosphatase, protein phosphatase 2A (PP2A), as well 
as phosphorylated Akt into PML nuclear bodies [27]. These 
bodies, however, are disrupted by the fusion protein, PML-
RARα, which is the hallmark of APL [5, 28]. This could be 
one of the reasons for Akt activation which is detected in 
APL [29]. Thus, this finding highlights the growing impor-
tance of Akt compartmentalization in human cancer patho-
genesis and treatment.
So far, over 100 Akt substrates have been identified 
[30]. Of these, about 40 which mediate the pleiotropic 
Akt functions have been characterized, including Bad, 
caspase-9, murine double minute 2 (MDM2), IĸB kinase 
(IKK) α, proline-rich Akt substrate 40-kDa (PRAS40) 40, 
the FOXO family of Forkhead transcription factors, apop-
tosis signal-regulated kinase 1 [ASK1, a negative regula-
tor of pro-apoptotic c-Jun N-terminal kinase (JNK)], Raf, 
p27Kip1, p21Cip1, glycogen synthase kinase 3β (GSK3β. Each 
of these substrates has a key role in the regulation of cell 
survival and proliferation, either directly or through an 
intermediary [16, 31]. A rare, oncogenetic, activating muta-
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tion (E17K) in the PH domain of Akt1 has been detected 
in some types of solid cancers (breast, colon, ovary). This 
mutation resulted in Akt constitutive binding to the plasma 
membrane and was leukemogenic in mice [32]. 
mTOR
mTOR is an atypical 289-kDa serine/threonine kinase, 
originally identified in the yeast Saccharomyces Cerevi-
siae, that belongs to the PI3K-related kinase family and 
displays a COOH-terminal catalytic domain with a high 
sequence homology to PI3K (Figure 2). This similar-
ity could explain the cross-inhibition of mTOR by drugs 
which target PI3K (see below) [33]. mTOR signaling is 
conserved in eukaryotes from plants and yeasts to mam-
mals. mTOR exists as two complexes, referred to as mTOR 
complex 1 (mTORC1) and mTORC2. mTORC1 is com-
prised of mTOR/Raptor/mLST8/PRAS40/FKBP38/Deptor 
and is sensitive to rapamycin and its derivatives (rapalogs). 
mTORC2 is composed of mTOR/Rictor/mLST8/SIN1/
Protor/Deptor and is generally described as being insensi-
tive to rapamycin/rapalogs, although long-term treatment 
of about 20% of cancer cell lines with rapamycin/rapa-
logs leads to dissociation of mTORC2 [34, 35]. mTORC1 
signaling integrates environmental clues (growth factors, 
hormones, nutrients, stressors) and information from the 
cell metabolic status. Thus, mTORC1 controls anabolic 
processes for promoting protein synthesis and cell growth 
[36]. mTORC1 regulates translation in response to nutri-
ents/growth factors by phosphorylating components of 
the protein synthesis machinery, including p70S6 kinase 
(p70S6K) and eukaryotic initiation factor 4E-binding pro-
tein 1 (4E-BP1). p70S6K phosphorylates the 40S ribosomal 
protein, S6, leading to active translation of mRNAs, while 
4E-BP1 phosphorylation by mTORC1 on several amino 
acidic residues (Ser37; Thr46; Ser65; Thr70) results in the 
release of the eukaryotic initiation factor 4E (eIF4E). eIF4E 
is a key component for translation of 5’ capped mRNAs, 
which include transcripts encoding growth promoting mol-
ecules, such as c-Myc, cyclin D1, cyclin-dependent kinase 
2, retinoblastoma protein, p27Kip1, vascular endothelial 
growth factor (VEGF), and signal activator and trans-
ducer of transcription 3 (STAT3) [34, 37]. Furthermore, 
mTORC1 negatively regulates autophagy, a non-apoptotic 
form of cell death, which is attracting much attention, as it 
could affect sensitivity of tumors (including leukemias) to 
various forms of therapy [38].
Akt-mediated regulation of mTORC1 activity involves 
several mechanisms. Akt inhibits TSC2 (Tuberous Scle-
rosis 2 or hamartin) function through direct phosphoryla-
tion. TSC2 is a GTPase-activating protein (GAP) which 
associates with TSC1 (Tuberous Sclerosis 1 or tuberin) 
for inactivating the small G protein Rheb (Ras homolog 
enriched in brain). TSC2 phosphorylation by Akt represses 
GAP activity of the TSC1/TSC2 complex, allowing Rheb 
to accumulate in a GTP-bound state. The mechanism by 
which Rheb-GTP activates mTORC1 has not been fully 
elucidated yet, although Rheb requires to be farnesylated 
for activating mTORC1 [39]. Thus, it could be inhibited by 
farnesyl-trasferase inhibitors (FTIs). Akt also phosphory-
lates PRAS40, an inhibitor of the interactions between 
mTORC1 and its substrates, and by doing so, prevents 
PRAS40 ability to suppress mTORC1 signaling [40]. 
Moreover, PRAS40 is a substrate of mTORC1 itself, and it 
has been demonstrated that mTORC1-mediated phosphor-
ylation of PRAS40 facilitates the removal of its inhibition 
on mTORC1 [41].
Moreover, Ras/Raf/mitogen-activated protein kinase 
kinase (MEK)/extracellular signal-regulated kinase (ERK) 
1/2 signaling positively regulates mTORC1 activity, as 
both ERK 1/2 and p90 ribosomal S6 kinase (p90RSK) phos-
Fig. 2.  A schematic presentation of mTOR structure. Some of the proteins interacting with mTOR domains are highlighted. 
The FRB domain is where the FKBP12 and rapamycin complex binds which is within the region that binds FKBP38. 
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phorylate TSC2, thus suppressing its inhibitory function 
on Rheb [42] (Figure 1). mTORC1 signal transduction is 
inhibited by the master metabolic regulator, energy-sensing 
AMP-dependent protein kinase (AMPK), given that AMPK 
phosphorylates and activates TSC2 [43]. 
The mechanisms for mTORC2 regulation have only 
begun to be revealed. However, mTORC2 activation 
requires PI3K and the TSC1/TSC2 complex, but is inde-
pendent of Rheb and is largely insensitive to either nutrients 
or energy conditions [44]. mTORC2 phosphorylates Akt on 
Ser473 which enhances subsequent Akt phosphorylation 
on Thr308 by PDK1 [45]. Moreover, mTORC2 plays a role 
in cytoskeleton organization by controlling actin polymer-
ization [46] and phosphorylates protein kinase C (PKC) α 
[44]. Another down-stream target of mTORC2 is serum- 
and glucocorticoid-induced protein kinase 1 (SGK1) [47]. 
The oncogenetic role of mTORC2 has been recently high-
lighted by an investigation that documented the importance 
of mTORC2 in the development and progression of pros-
tate cancers induced in mice by PTEN loss [48].
Akt and mTORC1/2 are linked to each other via posi-
tive and negative regulatory feedback circuits, which 
restrain their simultaneous hyperactivation through mech-
anisms which involve p70S6K and PI3K. Assuming that 
an equilibrium exists between mTORC1 and mTORC2, 
when mTORC1 is formed, it antagonizes the formation of 
mTORC2 and reduces Akt activity. Indeed, once mTORC1 
is activated through Akt, the former elicits a negative feed-
back loop for inhibiting Akt activity [34]. This negative 
regulation of Akt activity by mTORC1 is a consequence 
of p70S6K-mediated phosphorylation of insulin receptor 
substrate (IRS) 1 adapter protein, downstream of insu-
lin receptor and/or Insulin-like Growth Factor-1 Recep-
tor (IGF-1R) [49, 50]. Indeed, IRS-1 phosphorylation on 
Ser307 and Ser636/639 by p70S6K targets the adapter 
protein to proteasomal degradation [51]. Therefore, at least 
in principle, inhibition of mTORC1 activity by rapamy-
cin/rapalogs could result in hyperactivation of both Akt 
and its downstream targets. Such a phenomenon has been 
documented to occur both in vitro and in vivo [52, 53]. 
mTORC1 is capable of downregulating also IRS2 expres-
sion by enhancing its proteosomal degradation [54]. Con-
sistently, mTORC1 inhibition by the rapalog, RAD001, 
increased IRS2 expression and Akt phosphorylation levels 
in AML cells [55]. Recent work has also highlighted a 
p70S6K-mediated phosphorylation of Rictor on Thr1135. 
This phosphorylation event exerted a negative regulatory 
effect on the mTORC2-dependent phosphorylation of Akt 
in vivo [56]. Thus, both mTORC1 and mTORC2 control 
Akt activation. 
Nevertheless, the extent to which disruption of negative 
feedbacks mechanism actually limits the therapeutic effects 
of mTOR inhibitors in cancer patients in vivo remains to be 
determined [57].
Negative regulation of PI3K/Akt/mTOR signaling
A tight counter-regulation by phosphatases has emerged 
as a crucial process to control PI3K/Akt/mTOR-dependent 
signaling. PTEN is a dual specificity lipid/protein phospha-
tase that preferentially removes the 3’-phosphate mainly 
from PtdIns (3,4,5)P3 but is also active on phosphatidylino-
sitol 3,4 bisphosphate [PtdIns (3,4)P2], thereby antago-
nizing network signaling [58, 59]. PTEN silencing or 
inactivating mutations have been detected in a wide variety 
of human neoplasias (including prostatic and endometrium 
carcinomas, glioblastomas, melanoma, and T-cell acute 
lymphoblastic leukemia [60]) and this results in Akt/mTOR 
up-regulation. SHIP-1 and SHIP-2 (for Src homology 
domain-containing inositol phosphatase) are phosphatases 
capable of removing the 5-phosphate from PtdIns (3,4,5)P3 
to yield PtdIns (3,4)P2 [61]. An important role for SHIP-1 
in normal hematopoiesis has been recently described [62, 
63]. PP2A, which is now considered to be an oncosuppres-
sor, down-regulates Akt activity, through dephosphoryla-
tion of Thr308 [64]. Thr308 and Ser473 residues of Akt are 
also targeted by the two isoforms (1 and 2) of PH domain 
leucine-rich repeat protein phosphatase (PHLPP) [65].
Activation of PI3K/Akt/mTOR signals in AML
From 50% to 80% of patients with AML display Akt 
phosphorylated on either Thr308 or Ser473 (or both) [66-
71]. Both the disease-free survival and the overall survival 
were significantly shorter in AML cases where pathway 
up-regulation was documented [70, 72-74]. Poor prognosis 
of AML patients with elevated PI3K/Akt/mTOR signal-
ing could be also related to the fact that this pathway con-
trols the expression of the membrane ATP-binding cassette 
(ABC) transporter, multidrug resistance-associated protein 
1, which extrudes chemotherapeutic drugs from leukemic 
cells and is usually associated with a lower survival rate 
[75, 76].
Nevertheless, a more recent report has highlighted that 
constitutive activation of PI3K/Akt/mTOR signaling could 
be a favourable prognostic factor in de novo cases of AML. 
One hypothesis for the lower relapse rate in patients with 
enhanced PI3K/Akt/mTOR signaling is that it could drive 
immature leukemic cells (LSCs and CFU-L) into S phase, 
thus rendering them more susceptible to polychemotherapy 
[77]. 
Causes of PI3K/Akt/mTOR signaling up-regulation in 
AML may be the result of several factors, including activat-
ing mutations of Fms-like tyrosine kinase 3 (FLT3) receptor 
[71] and c-Kit tyrosine kinase receptor [78], N- or K-Ras 
mutations [79], PI3K p110β and/or δ overexpression [80-
82], low levels of PP2A [70], autocrine/paracrine secretion 
of growth factors such as IGF-1 [82-84] and VEGF [85, 
86]. Overexpression of PDK1 has been reported in 45% 
of a cohort of 66 AML patients, however it was related to 
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PKC hyperphosphorylation, while the relationship (if any) 
with Thr308 Akt up-regulation was not investigated [87]. 
Interactions between leukemic cells and bone marrow stro-
mal cells through CXCR4  (a GPCR which is abundantly 
expressed on leukemic cell surface where it is up-regulated 
by hypoxic conditions [88, 89]) and its physiological ligand, 
CXCL12, produced by stromal cells [89, 90], could result 
in PI3K/Akt/mTOR activation [91]. Furthermore, interac-
tions between β1 integrins on AML cells and stromal fibro-
nectin could lead to pathway activation [92, 93], possibly 
through up-regulation of integrin-linked kinase 1 (ILK1) 
which is involved in Akt phosphorylation on Ser473 in a 
PI3K-dependent manner in AML cells [94]. The ability of 
ILK1 to function as a Ser473 Akt kinase could be related to 
the fact that ILK1 interacted with Rictor and was required 
for Akt phosphorylation by mTORC2 on Ser473 [95]. Pos-
sible causes of pathway activation in AML cells are high-
lighted in Figure 3.
No activating mutations in p110α PI3K [96] or Akt1 
PH domain [70, 97] have been detected so far in AML 
patients. Although PTEN is deleted in many solid cancers 
and T-cell acute lymphoblastic leukemia, PTEN deletion 
is extremely rare in AML [66, 69, 70]. PTEN can be inac-
tivated by post-translational mechanisms, including phos-
phorylation at the COOH-terminal regulatory domain. 
This phosphorylative event stabilizes PTEN molecule but 
makes it less active towards PtdIns (3,4,5)P3, thus resulting 
in Akt up-regulation [98]. PTEN phosphorylation has been 
reported in AML patients where it was significantly associ-
ated with high levels of p-Akt and with shorter overall sur-
vival [99]. However, subsequent studies could not confirm 
these findings [70, 74]. A reassessment of the PTEN role in 
AML could be important, as in mice, hematopoietic stem 
cells without functional PTEN, began multiplying rapidly, 
showed diminished self-renewal capacity, and started to 
move out of the bone marrow, colonizing distant organs, 
and originating a leukemic-like disease [100, 101]. Of note, 
these effects were mostly mediated by mTOR, as rapamy-
cin not only depleted LSCs, but also restored normal hema-
topoietic stem cell function [101].
It is conceivable that several concomitant extrinsic and 
intrinsic causes converge to activate PI3K/Akt/mTOR sig-
naling in AML patients, even if this fundamental issue has 
not been thoroughly investigated. Indeed, in the only pub-
lished study, it was demonstrated that, in a small cohort of 
patients, overexpression of PI3K p110δ [81] could coexist 
with activating FLT3 and Ras mutations. It has also been 
reported that mTORC1 activation was independent of PI3K/
Fig. 3. Constitutive activation of PI3K/Akt signaling in AML cells. In this cartoon, mutated (Mut) C-Kit, FLT3, or Ras, 
and autocrine/paracrine secretion of growth factors (VEGF, IGF-1) impinge upon increased levels of p110β and/or 
p110δ PI3K. This results in high levels of PtdIns (3,4,5)P3 synthesized at the plasma membrane from PtdIns (4,5)P2. 
PtdIns (3,4,5)P3 recruits at the plasma membrane both PDK1 and inactive Akt (Akt off). PDK1 phoshorylates Akt on 
Thr308, whereas phosphorylation on Ser473 is driven by mTORC2. These two phosphorylative events fully activates 
Akt (Akt on). Bone marrow stromal cells secrete CXCL12 and fibronectin. Fibronectin, by interacting with β integrins, 
could activate ILK which, in turn, stimulates mTORC2 activity on Ser473 Akt. CXCL12 binds its receptor CXCR4, 
a GPCR which results in increased PI3K activity. Bone marrow stromal cells could also secrete VEGF and IGF-1. 
Activated Akt migrates to both nucleus and cytosol to phosphorylate its substrates. 
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Akt activity in AML patients [55]. In some AML cases, it 
has been documented that either MEK/ERK 1/2 [102] or 
Lyn signaling [103] could be up-stream of mTORC1. TSC2 
gene expression was found to be down-regulated in AML 
patients, most likely due to promoter hypermethylation. 
However, it is not known if it impinged on mTORC1 acti-
vation [104].
It should be emphasized here that PI3K/Akt/mTOR net-
work up-regulation has been detected not only in the bulk of 
the AML blasts, but also in LSCs transplanted in non-obese 
diabetic/severe combined immunodeficiency (NOD/SCID) 
mice, where it exerted a powerful pro-survival effect. This 
finding suggests that therapeutic targeting of this pathway 
has the potential for eradicating AML [105]. 
Targeting PI3K/Akt/mTOR module in AML
Either used alone or in combination with other drugs, 
PI3K/Akt/mTOR signaling inhibitors have been proven 
useful for down-regulating cell proliferation and inducing 
apoptosis in pre-clinical settings of AML, using cell lines 
or animal models. However, clinical trials of these com-
pounds are limited. We shall now highlight some com-
pounds which have been used for targeting PI3K/Akt/
mTOR signaling in AML cells.
PI3K inhibitors
Wortmannin and LY294002 are the best characterized 
PI3K inhibitors that have been widely used as research 
tools to elucidate the role of PI3K/Akt/mTOR signaling 
in various tumor cells. Both inhibitors are cell-permeable 
and low molecular weight compounds. Wortmannin is a 
natural metabolite produced by Penicillium wortmanni and 
inhibits all class PI3K members with a 50% inhibitory con-
centration (IC50) in vitro of 2-5 nM, while inhibiting other 
kinases [mTOR, DNA-dependent protein kinase (DNA-
PK), and ataxia telangiectasia mutated kinase] with higher 
IC50 values [106]. It is interesting that DNA-PK was found 
to phosphorylate Akt on Ser473 under conditions of DNA 
damage [107].
LY294002 is a flavonoid-based synthetic compound and 
inhibits PI3K with an IC50 of 1-20 μM. However, LY294002 
blocks not only PI3K activity but also mTOR, DNA-PK, 
Pim kinase, polo-like kinase, and CK2 to the same extent 
as PI3K [106]. Both wortmannin and LY294002 bind to 
the p110 catalytic subunit of PI3K, leading to the blockade 
of ATP bound to the active portion. PI3K inhibition with 
LY294002 is reversible and ATP-competitive while wort-
mannin irreversibly inhibits PI3K in a non-ATP-competi-
tive manner [106]. 
Wortmannin and LY294002 have been used in pre-
clinical models of AML where they displayed powerful 
cytotoxic effects in vitro [66, 79, 108, 109]. Since the insol-
ubility in aqueous solutions and high toxicity of both inhib-
itors precluded their clinical application, efforts to develop 
PI3K inhibitors more suitable for clinical use are currently 
underway [110]. 
Several selective inhibitors of p110 PI3K isoforms are 
now available [111]. IC87114 is a compound that selec-
tively inhibits the p110δ isoform of PI3K. IC87114 down-
regulated p-Akt and p-FOXO3a, reduced proliferation, and 
induced apoptosis in AML primary cells overexpressing 
p110δPI3K. Moreover, it synergized with etoposide [81]. 
In primary APL cells, both IC87114 and TGX-115 (a p110β 
PI3K-selective inhibitor) triggered apoptosis in the pres-
ence or in the absence of the differentiating agent, ATRA 
[29]. 
Conceivably, the use of selective PI3K isoform inhibi-
tors could be associated with less undesirable side effects 
than the use of broad spectrum PI3K inhibitors [111]. For 
example, it is established that insulin control of glucose 
homeostasis is mainly mediated through p110α PI3K [112] 
and, to a much lower extent, by p110β PI3K [113]. 
Akt inhibitors
Perifosine is a zwitterionic, water soluble, synthetic 
alkylphosphocholine with oral bioavailability that inhibits 
Akt phosphorylation through interaction with the Akt PH 
domain, resulting in disruption of its membrane targeting. 
Interestingly, recent evidence has documented that perifos-
ine targets both mTORC1 and mTORC2 activity by down-
regulating the levels of mTOR, raptor, rictor, p70S6K, 
and 4E-BP1, owing to their enhanced degradation [114]. 
Perifosine reduced cell proliferation and induced apoptosis 
accompanied by Akt dephosphorylation in a wide variety 
of neoplasias, including AML [115]. Perifosine synergized 
with etoposide in AML blasts, and reduced the clonogenic 
activity of CD34+ cells from leukemic patients, but not from 
healthy donors [116]. Moreover, perifosine synergized 
with histone deacetylase inhibitors [117] or pro-apoptotic 
TRAIL (TNF-related Apoptosis Inducing Ligand) in AML 
cell lines and primary cells displaying Akt constitutive acti-
vation [118]. However, perifosine also targeted the MER/
ERK 1/2 pro-survival pathway and activated pro-apoptotic 
JNK, [116-120] therefore it could not be considered spe-
cific for the Akt pathway. A phase 1 clinical trial combining 
perifosine and UCN-01 (a staurosporine derivative which 
inhibits PDK1) (NCT00301938) and a phase II clinical 
trial with perifosine alone (NCT00391560) have been per-
formed in patients with refractory/relapsed AML, but the 
results have not yet been disclosed. 
Akt-I-1/2, a synthetic reversible allosteric inhibitor, is 
an Akt1/Akt2 isoform-specific inhibitor that forms a PH 
domain-dependent inactive conformation with Akt1 and 
Akt2 [121]. Akt-I-1/2 inhibited cell proliferation and clo-
nogenic properties, and induced apoptosis in AML cells 
with high-risk cytogenetic changes/abnormalities [70]. 
However, it is at present unknown which Akt isoforms are 
expressed by AML blasts.
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mTOR inhibitors
mTOR inhibitors are by far the most developed class 
of compounds which target the PI3K/Akt/mTOR pathway. 
They include: rapamycin (sirolimus, a macrolide derived 
from the bacterium Streptomyces hygroscopicus, originally 
discovered in a soil sample collected on Easter Island) and 
its derivatives CCI-779 (temsirolimus), RAD001 (evero-
limus), and AP23573 (deforolimus) [122]. Temsirolimus 
was approved by US Food and Drug Administration in 
2007 for the first-line treatment of poor prognosis patients 
with advanced renal cell carcinoma. The overall survival of 
treated patients was increased by nearly 50% (~ 3 months) 
relative to the control group [123]. Some clinical benefits of 
rapamycin/rapalogs have been reported also against endo-
metrial carcinoma and mantle cell lymphoma, however, the 
overall objective response rates in major solid tumors have 
been modest [124].
Rapamycin and rapalogs do not target the catalytic site 
of mTORC1, but rather bind its immunophilin, FK506 
binding protein 12 (FKBP12) (Figure 2). The rapamycin/
FKBP12 complex then binds mTORC1 and inhibits down-
stream signaling events [125]. Thus, rapamycin and rapa-
logs act as allosteric mTORC1 inhibitors. Recent evidence 
has documented that complex formation with FKBP12 is 
not an absolute requirement for repression of mTORC1 
activity by rapamycin/rapalogs, however, in the absence 
of FKBP12, the drugs display a 100 to 1000-fold lower 
potency than in the presence of the immunophilin [126]. 
Available data suggest that rapamycin treatment, over 
long time periods, also targets mTORC2 [127]. Accord-
ingly, both CCI-779 and RAD001 (10-20 nM) inhibited 
Akt phosphorylation on Ser473 in AML cells in vitro and 
in patients in vivo after a 24 h incubation, through suppres-
sion of the mTORC2 assembly [128]. In contrast, it has 
been documented that RAD001 (10 nM for 24 h) increased 
Akt phosphorylation in vitro on Ser473 in AML samples 
displaying constitutive PI3K/Akt activation [55]. Since a 
neutralizing monoclonal antibody to the IGF-1R α-subunit, 
reversed the RAD001-induced increase of Akt phosphory-
lation and RAD001 treatment led to a significant increase 
in IRS2 protein expression, it was concluded that p-Akt up-
regulation could be explained by the existence of an IGF-1/
IGF-1R autocrine loop, as well as by increased expression 
of IRS2. At present, it is not easy to reconcile these contra-
dictory findings. 
Rapamycin had only a modest effect on primary AML 
cell survival in liquid culture, however, it markedly down-
regulated AML blast clonogenicity while sparing normal 
hematopoietic precursors [129]. Accordingly, others have 
reported that rapamycin led to only a slight decrease in 
AML blast survival in short term cultures, whereas in long 
term cultures the effect was more pronounced [105]. These 
results suggested that the target of rapamycin is the prolif-
erating contingent of the leukemic clone, rather than the 
bulk of AML blasts which are predominantly blocked in the 
G0/G1 phase of the cell cycle. 
However, rapamycin cytotoxicity in short term cul-
tures could be dramatically increased by co-treatment with 
etoposide. Importantly, etoposide toxicity on CD34+ cells 
from healthy donors was not enhanced by addition of rapa-
mycin. Of note, co-incubation with rapamycin enhanced 
etoposide-mediated decrease in the engraftment of AML 
cells in NOD/SCID mice, suggesting the drugs also tar-
geted putative LCSs [105]. 
The rapalog RAD001 synergized with both ATRA and 
histone acetylase inhibitors in inducing growth arrest and 
differentiation of APL cell lines [130, 131].
A few phase I/II clinical trials with rapamycin and rapa-
logs have been performed in patients with relapsed/refrac-
tory AML. Rapamycin induced a partial response in 4 of 9 
adult patients with de novo or secondary AML, who dis-
played activation of mTORC1 signaling, as documented by 
increased levels of p-p70S6K and p-4E-BP1 [129]. RAD001 
has been evaluated in a phase I clinical trial in patients with 
relapsed/refractory hematologic malignancies, including 
AML [132]. However, no AML patients achieved a com-
plete or even partial response. AP23573 has been tested in 
a phase II study in 22 patients with AML [133]. Only one 
patient displayed an objective hematological improvement, 
consisting of normalization of neutrophils. A significant 
reduction in mTORC1 activity was observed in response 
to the drug, as documented by decreased p-4E-BP1 levels. 
A recent phase I study in which rapamycin was combined 
with MEC (mitoxantrone, etoposide, cytarabine) polyche-
motherapy failed to demonstrate any synergistic effect 
of the combination in relapsed/refractory AML patients, 
even if proof of rapamycin biological activity in vivo was 
detected, consisting in the dephosphorylation of p70S6K 
[134]. Several clinical trials with rapamycin/rapalogs com-
bined with chemotherapeutic agents are now underway in 
AML patients [135].
Moreover, a phase I study has recently documented 
the efficacy, in elderly AML patients, of the combination 
etoposide and tipifarnib (R11577, an FTI). Intriguingly, 
the effect of tipifarnib was not always related to Ras inhi-
bition, but rather to inhibition of Rheb farnesylation and, 
consequently, of mTORC1 signaling, as documented by 
decreased levels of p-p70S6K and of its substrate, p-S6 
[136]. 
Dual PI3K/mTOR inhibitors
The rationale for using dual PI3K/mTOR inhibitors is 
that mTORC1 allosteric inhibitors, such as rapamycin/rap-
alogues, could hyperactivate Akt through p70S6K/PI3K, 
as discussed earlier in this review. Moreover, it is now 
emerging that rapamycin/rapalogs have only modest effi-
cacy on total translation rates, and the effects are cell-type 
specific. In contrast, small molecules designed for inhibit-
ing the catalytic site of mTOR, were much more effective 
in this respect, especially in cancer cells [137-141]. Such 
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a phenomenon has been recently reported to occur also in 
AML cells, where rapamycin was unable to block protein 
synthesis, owing to a failure in inducing 4E-BP1 dephos-
phorylation [142]. Furthermore, in some AML cases, 
mTORC1 activity does not seem to be under the control of 
PI3K/Akt, despite concomitant PI3K/Akt activation [103]. 
Therefore, the use of a single inhibitor which targets both 
PI3K and mTORC1 catalytic sites could present substantial 
advantages over drugs which only target either PI3K/Akt 
or mTORC1. PI-103 is a pyridonylfuranopyrimidine class 
synthetic molecule that represses the activity of both class 
IA and IB PI3Ks, as well as of mTORC1/mTORC2 [143, 
144]. Two papers have documented the efficacy of PI-103 
in pre-clinical settings of AML. It has been reported that 
PI-103, which itself displayed only modest pro-apoptotic 
activity, acted synergistically with Nutlin-3 (an MDM2 
inhibitor) [145, 146], to induce apoptosis in a wild-type 
p53-dependent fashion in AML cell lines and primary cells 
[147]. Another group demonstrated that PI-103 was mainly 
cytostatic for AML cell lines. However, in AML blast cells, 
PI-103 inhibited leukemic proliferation and CFU-L clono-
genicity, induced mitochondrial apoptosis, and synergized 
with etoposide [148]. Of note, PI-103 was not apoptogenic 
in CD34+ cells from healthy donors and had only moder-
ate effects on their clonogenic and proliferative activities. 
Since either RAD001 or IC87114 did not induce apoptosis 
in AML primary cells, it was concluded that dual-targeted 
therapy against PI3K/Akt and mTOR with PI-103 may be 
of therapeutic value in AML [148]. 
Nevertheless, it is conceivable that the new frontier in 
mTOR inhibition will be represented by the second gen-
eration, ATP-competitive mTOR inhibitors which bind 
the active site of both mTORC1 and mTORC2 [137-140]. 
These drugs target mTOR signaling functions in a global 
way, so that they are expected to yield a deeper and broader 
antitumor response in the clinic. However, global inhibi-
tion of mTOR is expected to be accompanied by greater 
toxicity to normal cells [149].
CONCLUSIONS
In this review, we have documented that the PI3K/Akt/
mTOR pathway influences proliferation, survival, and drug 
resistance of AML cells. However, there still are many 
unresolved problems regarding the relevance of PI3K/Akt/
mTOR pathway up-regulation and its druggability in AML 
patients. We have a very limited knowledge of the down-
stream targets (genes/proteins) of this pathway in AML 
cells. Therefore, more detailed investigations of these tar-
gets are highly desirable. Indeed, data emerging from gene 
expression and proteome/phosphoproteome analysis could 
pave the way for functional studies which could then pro-
vide valuable information for improving future therapeutic 
strategies. At present, we do not know what is the most 
effective target in the pathway, and whether combinations 
of horizontal or vertical blockade of the signaling cascade 
may be more effective than blocking at a single node [150].
As with all molecularly targeted approaches, pharma-
codynamic markers are necessary to direct therapeutic 
development of PI3K/Akt/mTOR inhibitors. Hence, clini-
cal trials should examine the inhibitor effects on PI3K/Akt/
mTOR targets to establish the best predictor of response 
[151]. However, no predictive markers for AML patients 
with a high probability of responding to PI3K/Akt/mTOR 
inhibition, or biomarkers of dose/efficacy, have been vali-
dated. Quantitative flow cytometry appears particularly 
well suited for this kind of analysis, because it offers obvi-
ous advantages over other techniques (western blot, for 
example), including quickness, a much lower number of 
cells required to perform the assay, and the possibility of 
identifying different subclones in the leukemic population 
by co-immunostaining with multiple antibodies to surface 
antigens. Accordingly, flow cytometry is rapidly becoming 
the choice analytical technique to study PI3K/Akt/mTOR 
pathway activation in AML patients [70, 133, 152, 153]. 
Another promising quantitative technique requiring a lim-
ited number of cells, which has been already applied to the 
study of AML patients samples, is represented by reverse-
phase protein arrays [74].
It is highly unlikely that inhibition of a single signal-
ing pathway will achieve long-lasting remissions or cure in 
AML, especially for refractory/relapsed patients. However, 
combining PI3K/Akt/mTOR inhibitors with conventional 
chemotherapy drugs, differentiation inducers (ATRA and/or 
arsenic trioxide), or innovative (e.g. TRAIL) agents could 
be a very effective therapeutic option for AML patients, as 
indicated by results obtained in pre-clinical settings. 
The spectacular effect of Bcr-Abl tyrosine kinase inhib-
itors, such as imatinib for the treatment of chronic myelog-
enous leukemia (CML) patients in the chronic phase of the 
disease [154], has fed optimism that modulators of signal 
transduction networks might be very effective also in other 
types of cancer. However, clinical trials performed with 
small molecules targeting the PI3K/Akt/mTOR pathway 
have mostly given a disappointing outcome. This fact has 
led to the suggestion that imatinib success in CML may be 
the exception and not the rule, because imatinib is one of 
the few examples of a drug targeting the anomaly which 
constitutes the underlying pathologic event in the forma-
tion of the disorder [155]. Human cancers are known to 
evolve through a multistage process which can extend over 
a period of several years. Therefore, they progressively 
accumulate mutations and epigenetic anomalies in expres-
sion of multiple genes [156]. As a consequence, neoplastic 
disorders are characterized by multiple signaling abnor-
malities and the deregulated pathways are extremely redun-
dant. Furthermore, the hierarchy of anomalies has not been 
established in many tumors. Therefore, it could be very dif-
ficult to find the right target or combinations of target. 
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AML is no exception to this rule. However, the continu-
ous development of molecularly targeted drugs displaying 
higher selectivity, coupled with additional mechanistic 
studies and advances in profiling the signaling networks of 
cancer cells, should make it possible to exploit deregulation 
of the PI3K/Akt/mTOR cascade to achieve more effective 
and less toxic therapies for AML. 
CONFLICT OF INTEREST
The authors have no conflict of interests to declare.
ACKNOWLEDGEMENTS
This work was supported by grants from: Fondazione 
del Monte di Bologna e Ravenna and Progetti Strategici 
Università di Bologna EF 2006 to AMM. JAM was sup-
ported in part by a grant from the National Institutes of 
Health (USA) (R01098195).
REFERENCES
1.  Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern 
W. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 
2004;50:197-222.
2.  Kantarjian H, O'Brien S, Cortes J, Wierda W, Faderl S, Gar-
cia-Manero G, Issa JP, Estey E, Keating M, Freireich EJ. 
Therapeutic advances in leukemia and myelodysplastic syn-
drome over the past 40 years. Cancer 2008;113:1933-52.
3.  Ravandi F, Burnett AK, Agura ED, Kantarjian HM. Prog-
ress in the treatment of acute myeloid leukemia. Cancer 
2007;110:1900-10.
4.  Stapnes C, Gjertsen BT, Reikvam H, Bruserud O. Targeted 
therapy in acute myeloid leukaemia: current status and future 
directions. Expert Opin Investig Drugs 2009;18:433-55.
5.  Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin MC, de 
The H. Therapy-induced PML/RARA proteolysis and acute 
promyelocytic leukemia cure. Clin Cancer Res 2009;15:6321-
6.
6.  Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell 
niche: current concepts and therapeutic opportunities. Blood 
2009;114:1150-7.
7.  Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Basecke 
J, Libra M, Nicoletti F, Stivala F, Milella M, Tafuri A, Cer-
vello M, Martelli AM, et al. Targeting the leukemic stem cell: 
the Holy Grail of leukemia therapy. Leukemia 2009;23:25-
42.
8.  McCubrey JA, Abrams SL, Ligresti G, Misaghian N, Wong 
EW, Steelman LS, Basecke J, Troppmair J, Libra M, Nicoletti 
F, Molton S, McMahon M, et al. Involvement of p53 and Raf/
MEK/ERK pathways in hematopoietic drug resistance. Leu-
kemia 2008;22:2080-90.
9.  Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig 
DE, Basecke J, Libra M, Stivala F, Milella M, Tafuri A, 
Lunghi P, Bonati A, et al. Contributions of the Raf/MEK/
ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to 
leukemia. Leukemia 2008;22:686-707.
10.  Scholl C, Gilliland DG, Frohling S. Deregulation of sig-
naling pathways in acute myeloid leukemia. Semin Oncol 
2008;35:336-45.
11.  Yuan TL, Cantley LC. PI3K pathway alterations in cancer: 
variations on a theme. Oncogene 2008;27:5497-510.
12.  Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blalock 
WL, Billi AM, Manzoli L, McCubrey JA, Cocco L. Targeting 
the phosphatidylinositol 3-kinase/Akt/mammalian target of 
rapamycin module for acute myelogenous leukemia therapy: 
from bench to bedside. Curr Med Chem 2007;14:2009-23.
13.  Horn S, Bergholz U, Jucker M, McCubrey JA, Trumper L, 
Stocking C, Basecke J. Mutations in the catalytic subunit of 
class IA PI3K confer leukemogenic potential to hematopoi-
etic cells. Oncogene 2008;27:4096-106.
14.  Brazil DP, Yang ZZ, Hemmings BA. Advances in protein 
kinase B signalling: AKTion on multiple fronts. Trends Bio-
chem Sci 2004;29:233-42.
15.  Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phos-
phoinositide 3-kinase pathway in cancer. Nat Rev Drug 
Discov 2009;8:627-44.
16.  Franke TF. PI3K/Akt: getting it right matters. Oncogene 
2008;27:6473-88.
17.  Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase 
isoforms be targeted in cancer? Curr Opin Cell Biol 
2009;21:199-208.
18.  Fruman DA, Bismuth G. Fine tuning the immune response 
with PI3K. Immunol Rev 2009;228:253-72.
19.  Kok K, Geering B, Vanhaesebroeck B. Regulation of phos-
phoinositide 3-kinase expression in health and disease. 
Trends Biochem Sci 2009;34:115-27.
20.  Backer JM. The regulation and function of Class III PI3Ks: 
novel roles for Vps34. Biochem J 2008;410:1-17.
21.  Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile 
F, Nicoletti F, Stivala F, McCubrey JA, Libra M. PIK3CA 
mutations in human solid tumors: role in sensitivity to vari-
ous therapeutic approaches. Cell Cycle 2009;8:1352-8.
22.  Denley A, Kang S, Karst U, Vogt PK. Oncogenic signaling of 
class I PI3K isoforms. Oncogene 2008;27:2561-74.
23.  Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transfor-
mation. Oncogene 2008;27:5486-96.
24.  Bae SS, Cho H, Mu J, Birnbaum MJ. Isoform-specific regu-
lation of insulin-dependent glucose uptake by Akt/protein 
kinase B. J Biol Chem 2003;278:49530-6.
25.  Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, 
Ayala R, Danino M, Karlan BY, Slamon DJ. Overexpression 
of AKT2/protein kinase Bbeta leads to up-regulation of beta1 
integrins, increased invasion, and metastasis of human breast 
and ovarian cancer cells. Cancer Res 2003;63:196-206.
26.  Martelli AM, Faenza I, Billi AM, Manzoli L, Evangelisti C, 
Fala F, Cocco L. Intranuclear 3'-phosphoinositide metabo-
lism and Akt signaling: new mechanisms for tumorigenesis 
and protection against apoptosis? Cell Signal 2006;18:1101-
7.
Oncotarget 2010; 1: 89-103www.impactjournals.com/oncotarget/
99
27.  Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cor-
don-Cardo C, Pandolfi PP. Identification of a tumour sup-
pressor network opposing nuclear Akt function. Nature 
2006;441:523-7.
28.  Wojiski S, Guibal FC, Kindler T, Lee BH, Jesneck JL, Fabian 
A, Tenen DG, Gilliland DG. PML-RARalpha initiates leu-
kemia by conferring properties of self-renewal to committed 
promyelocytic progenitors. Leukemia 2009;23:1462-71.
29.  Billottet C, Banerjee L, Vanhaesebroeck B, Khwaja A. Inhi-
bition of class I phosphoinositide 3-kinase activity impairs 
proliferation and triggers apoptosis in acute promyelocytic 
leukemia without affecting atra-induced differentiation. 
Cancer Res 2009;69:1027-36.
30.  Manning BD, Cantley LC. AKT/PKB signaling: navigating 
downstream. Cell 2007;129:1261-74.
31.  Downward J. PI 3-kinase, Akt and cell survival. Semin Cell 
Dev Biol 2004;15:177-82.
32.  Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Rob-
bins CM, Hostetter G, Boguslawski S, Moses TY, Savage 
S, Uhlik M, Lin A, et al. A transforming mutation in the 
pleckstrin homology domain of AKT1 in cancer. Nature 
2007;448:439-44.
33.  Memmott RM, Dennis PA. Akt-dependent and -indepen-
dent mechanisms of mTOR regulation in cancer. Cell Signal 
2009;21:656-64.
34.  Dunlop EA, Tee AR. Mammalian target of rapamycin com-
plex 1: signalling inputs, substrates and feedback mecha-
nisms. Cell Signal 2009;21:827-35.
35.  Rosner M, Hengstschlager M. Cytoplasmic and nuclear dis-
tribution of the protein complexes mTORC1 and mTORC2: 
rapamycin triggers dephosphorylation and delocalization of 
the mTORC2 components rictor and sin1. Hum Mol Genet 
2008;17:2934-48.
36.  Tamburini J, Green AS, Chapuis N, Bardet V, Lacombe 
C, Mayeux P, Bouscary D. Targeting translation in acute 
myeloid leukemia: A new paradigm for therapy? Cell Cycle 
2009;8:3893-9.
37.  Mamane Y, Petroulakis E, LeBacquer O, Sonenberg 
N. mTOR, translation initiation and cancer. Oncogene 
2006;25:6416-22.
38.  Crazzolara R, Cisterne A, Thien M, Hewson J, Baraz R, 
Bradstock KF, Bendall LJ. Potentiating effects of RAD001 
(Everolimus) on vincristine therapy in childhood acute lym-
phoblastic leukemia. Blood 2009;113:3297-306.
39.  Mavrakis KJ, Zhu H, Silva RL, Mills JR, Teruya-Feldstein 
J, Lowe SW, Tam W, Pelletier J, Wendel HG. Tumorigenic 
activity and therapeutic inhibition of Rheb GTPase. Genes 
Dev 2008;22:2178-88.
40.  Wang L, Harris TE, Lawrence JC, Jr. Regulation of proline-
rich Akt substrate of 40 kDa (PRAS40) function by mam-
malian target of rapamycin complex 1 (mTORC1)-mediated 
phosphorylation. J Biol Chem 2008;283:15619-27.
41.  Fonseca BD, Smith EM, Lee VH, MacKintosh C, Proud CG. 
PRAS40 is a target for mammalian target of rapamycin com-
plex 1 and is required for signaling downstream of this com-
plex. J Biol Chem 2007;282:24514-24.
42.  Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi 
PP. Phosphorylation and functional inactivation of TSC2 by 
Erk implications for tuberous sclerosis and cancer pathogen-
esis. Cell 2005;121:179-93.
43.  Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, 
Menendez JA. AMPK: Evidence for an energy-sensing cyto-
kinetic tumor suppressor. Cell Cycle 2009;8:3679-83.
44.  Huang J, Manning BD. A complex interplay between Akt, 
TSC2 and the two mTOR complexes. Biochem Soc Trans 
2009;37:217-22.
45.  Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phos-
phorylation and regulation of Akt/PKB by the rictor-mTOR 
complex. Science 2005;307:1098-101.
46.  Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall 
A, Hall MN. Mammalian TOR complex 2 controls the actin 
cytoskeleton and is rapamycin insensitive. Nat Cell Biol 
2004;6:1122-8.
47.  Garcia-Martinez JM, Alessi DR. mTOR complex 2 
(mTORC2) controls hydrophobic motif phosphorylation 
and activation of serum- and glucocorticoid-induced protein 
kinase 1 (SGK1). Biochem J 2008;416:375-85.
48.  Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, 
Sheen JH, Mullholland DJ, Magnuson MA, Wu H, Sabatini 
DM. mTOR complex 2 is required for the development of 
prostate cancer induced by Pten loss in mice. Cancer Cell 
2009;15:148-59.
49.  Shah OJ, Wang Z, Hunter T. Inappropriate activation of the 
TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, 
insulin resistance, and cell survival deficiencies. Curr Biol 
2004;14:1650-6.
50.  Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 
2007;12:487-502.
51.  Xu X, Sarikas A, Dias-Santagata DC, Dolios G, Lafontant 
PJ, Tsai SC, Zhu W, Nakajima H, Nakajima HO, Field LJ, 
Wang R, Pan ZQ. The CUL7 E3 ubiquitin ligase targets insu-
lin receptor substrate 1 for ubiquitin-dependent degradation. 
Mol Cell 2008;30:403-14.
52.  Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian 
target of rapamycin inhibitors activate the AKT kinase in mul-
tiple myeloma cells by up-regulating the insulin-like growth 
factor receptor/insulin receptor substrate-1/phosphatidylino-
sitol 3-kinase cascade. Mol Cancer Ther 2005;4:1533-40.
53.  Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys 
L, Maira SM, Kwiatkowski D, Lane HA. Increased AKT 
S473 phosphorylation after mTORC1 inhibition is rictor 
dependent and does not predict tumor cell response to PI3K/
mTOR inhibition. Mol Cancer Ther 2009;8:742-53.
54.  Sriburi R, Jackowski S, Mori K, Brewer JW. XBP1: a link 
between the unfolded protein response, lipid biosynthesis, 
and biogenesis of the endoplasmic reticulum. J Cell Biol 
2004;167:35-41.
55.  Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Wil-
lems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bous-
cary D. Mammalian target of rapamycin (mTOR) inhibition 
activates phosphatidylinositol 3-kinase/Akt by up-regulat-
ing insulin-like growth factor-1 receptor signaling in acute 
myeloid leukemia: rationale for therapeutic inhibition of both 
pathways. Blood 2008;111:379-82.
56.  Dibble CC, Asara JM, Manning BD. Characterization of 
Rictor phosphorylation sites reveals direct regulation of 
Oncotarget 2010; 1: 89-103www.impactjournals.com/oncotarget/
100
mTOR complex 2 by S6K1. Mol Cell Biol 2009;29:5657-70.
57.  O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith 
D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga 
J, Rosen N. mTOR inhibition induces upstream recep-
tor tyrosine kinase signaling and activates Akt. Cancer Res 
2006;66:1500-8.
58.  Keniry M, Parsons R. The role of PTEN signaling per-
turbations in cancer and in targeted therapy. Oncogene 
2008;27:5477-85.
59.  Stiles BL. Phosphatase and tensin homologue deleted on 
chromosome 10: extending its PTENtacles. Int J Biochem 
Cell Biol 2009;41:757-61.
60.  Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena 
L, Ahn Y, Dahlberg S, Neuberg D, Moreau LA, Winter SS, 
Larson R, Zhang J, et al. High frequency of PTEN, PI3K and 
AKT abnormalities in T cell acute lymphoblastic leukemia. 
Blood 2009;114:647-50.
61.  Kalesnikoff J, Sly LM, Hughes MR, Buchse T, Rauh MJ, Cao 
LP, Lam V, Mui A, Huber M, Krystal G. The role of SHIP in 
cytokine-induced signaling. Rev Physiol Biochem Pharma-
col 2003;149:87-103.
62.  Ong CJ, Ming-Lum A, Nodwell M, Ghanipour A, Yang L, 
Williams DE, Kim J, Demirjian L, Qasimi P, Ruschmann 
J, Cao LP, Ma K, et al. Small-molecule agonists of SHIP1 
inhibit the phosphoinositide 3-kinase pathway in hematopoi-
etic cells. Blood 2007;110:1942-9.
63.  Hazen AL, Smith MJ, Desponts C, Winter O, Moser K, Kerr 
WG. SHIP is required for a functional hematopoietic stem 
cell niche. Blood 2009;113:2924-33.
64.  Eichhorn PJ, Creyghton MP, Bernards R. Protein phospha-
tase 2A regulatory subunits and cancer. Biochim Biophys 
Acta 2009;1795:1-15.
65.  Brognard J, Newton AC. PHLiPPing the switch on Akt 
and protein kinase C signaling. Trends Endocrinol Metab 
2008;19:223-30.
66.  Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival 
of acute myeloid leukemia cells requires PI3 kinase activa-
tion. Blood 2003;102:972-80.
67.  Min YH, Eom JI, Cheong JW, Maeng HO, Kim JY, Jeung HK, 
Lee ST, Lee MH, Hahn JS, Ko YW. Constitutive phosphory-
lation of Akt/PKB protein in acute myeloid leukemia: its sig-
nificance as a prognostic variable. Leukemia 2003;17:995-7.
68.  Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B, 
Schwable J, Buerger H, Muller-Tidow C, Choudhary C, 
McMahon M, Berdel WE, Serve H. Constitutive activation 
of Akt by Flt3 internal tandem duplications is necessary for 
increased survival, proliferation, and myeloid transforma-
tion. Cancer Res 2005;65:9643-50.
69.  Grandage VL, Gale RE, Linch DC, Khwaja A. PI3-kinase/
Akt is constitutively active in primary acute myeloid leu-
kaemia cells and regulates survival and chemoresistance 
via NF-kappaB, Mapkinase and p53 pathways. Leukemia 
2005;19:586-94.
70.  Gallay N, Dos Santos C, Cuzin L, Bousquet M, Simmonet 
Gouy V, Chaussade C, Attal M, Payrastre B, Demur C, 
Recher C. The level of AKT phosphorylation on threonine 
308 but not on serine 473 is associated with high-risk cyto-
genetics and predicts poor overall survival in acute myeloid 
leukaemia. Leukemia 2009;23:1029-38.
71.  Muranyi AL, Dedhar S, Hogge DE. Combined inhibition of 
integrin linked kinase and FMS-like tyrosine kinase 3 is cyto-
toxic to acute myeloid leukemia progenitor cells. Exp Hema-
tol 2009;37:450-60.
72.  Min YH, Cheong JW, Kim JY, Eom JI, Lee ST, Hahn JS, 
Ko YW, Lee MH. Cytoplasmic mislocalization of p27Kip1 
protein is associated with constitutive phosphorylation of Akt 
or protein kinase B and poor prognosis in acute myelogenous 
leukemia. Cancer Res 2004;64:5225-31.
73.  Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, 
Konopleva M, Estey EH, Andreeff M. Simultaneous acti-
vation of multiple signal transduction pathways confers 
poor prognosis in acute myelogenous leukemia. Blood 
2006;108:2358-65.
74.  Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, 
Andreeff M, Coombes KR, Mills GB. Functional proteomic 
profiling of AML predicts response and survival. Blood 
2009;113:154-64.
75.  Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, 
Grafone T, Martinelli G, Conte R, Cocco L, McCubrey 
JA, Martelli AM. Multidrug resistance-associated protein 
1 expression is under the control of the phosphoinositide 
3 kinase/Akt signal transduction network in human acute 
myelogenous leukemia blasts. Leukemia 2007;21:427-38.
76.  Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T. 
MDR1 and MRP1 gene expression are independent predic-
tors for treatment outcome in adult acute myeloid leukaemia. 
Br J Haematol 2005;128:324-32.
77.  Tamburini J, Elie C, Bardet V, Chapuis N, Park S, Broet P, 
Cornillet-Lefebvre P, Lioure B, Ugo V, Blanchet O, Ifrah 
N, Witz F, et al. Constitutive phosphoinositide 3-kinase/Akt 
activation represents a favorable prognostic factor in de novo 
acute myelogenous leukemia patients. Blood 2007;110:1025-
8.
78.  Faderl S, Pal A, Bornmann W, Albitar M, Maxwell D, Van 
Q, Peng Z, Harris D, Liu Z, Hazan-Halevy I, Kantarjian HM, 
Estrov Z. Kit inhibitor APcK110 induces apoptosis and inhib-
its proliferation of acute myeloid leukemia cells. Cancer Res 
2009;69:3910-7.
79.  Birkenkamp KU, Geugien M, Schepers H, Westra J, Lem-
mink HH, Vellenga E. Constitutive NF-kappaB DNA-bind-
ing activity in AML is frequently mediated by a Ras/PI3-K/
PKB-dependent pathway. Leukemia 2004;18:103-12.
80.  Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick JS, Prie 
N, Verdier F, Vanhaesebroeck B, Muller O, Pesce F, Ifrah 
N, Hunault-Berger M, Berthou C, et al. Essential role for 
the p110delta isoform in phosphoinositide 3-kinase activa-
tion and cell proliferation in acute myeloid leukemia. Blood 
2005;106:1063-6.
81.  Billottet C, Grandage VL, Gale RE, Quattropani A, Rommel 
C, Vanhaesebroeck B, Khwaja A. A selective inhibitor of the 
p110delta isoform of PI 3-kinase inhibits AML cell prolifera-
tion and survival and increases the cytotoxic effects of VP16. 
Oncogene 2006;25:6648-59.
82.  Doepfner KT, Spertini O, Arcaro A. Autocrine insulin-like 
growth factor-I signaling promotes growth and survival of 
human acute myeloid leukemia cells via the phosphoinositide 
3-kinase/Akt pathway. Leukemia 2007;21:1921-30.
Oncotarget 2010; 1: 89-103www.impactjournals.com/oncotarget/
101
83.  Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, 
Grafone T, Martinelli G, McCubrey JA, Martelli AM. The 
insulin-like growth factor-I receptor kinase inhibitor NVP-
AEW541 induces apoptosis in acute myeloid leukemia cells 
exhibiting autocrine insulin-like growth factor-I secretion. 
Leukemia 2007;21:886-96.
84.  Wahner Hendrickson AE, Haluska P, Schneider PA, Loeger-
ing DA, Peterson KL, Attar R, Smith BD, Erlichman C, Got-
tardis M, Karp JE, Carboni JM, Kaufmann SH. Expression 
of insulin receptor isoform A and insulin-like growth factor-1 
receptor in human acute myelogenous leukemia: effect of the 
dual-receptor inhibitor BMS-536924 in vitro. Cancer Res 
2009;69:7635-43.
85.  Imai N, Miwa H, Shikami M, Suganuma K, Gotoh M, Hira-
matsu A, Wakabayashi M, Watarai M, Hanamura I, Imamura 
A, Mihara H, Shitara K, et al. Growth inhibition of AML 
cells with specific chromosome abnormalities by monoclonal 
antibodies to receptors for vascular endothelial growth factor. 
Leuk Res 2009;33:1650-7.
86.  Bohm A, Aichberger KJ, Mayerhofer M, Herrmann H, Flo-
rian S, Krauth MT, Derdak S, Samorapoompichit P, Sonneck 
K, Vales A, Gleixner KV, Pickl WF, et al. Targeting of mTOR 
is associated with decreased growth and decreased VEGF 
expression in acute myeloid leukaemia cells. Eur J Clin 
Invest 2009;39:395-405.
87.  Pearn L, Fisher J, Burnett AK, Darley RL. The role of PKC 
and PDK1 in monocyte lineage specification by Ras. Blood 
2007;109:4461-9.
88.  Fierro FA, Brenner S, Oelschlaegel U, Jacobi A, Knoth H, 
Ehninger G, Illmer T, Bornhauser M. Combining SDF-1/
CXCR4 antagonism and chemotherapy in relapsed acute 
myeloid leukemia. Leukemia 2009;23:393-6.
89.  Fiegl M, Samudio I, Clise-Dwyer K, Burks JK, Mnjoyan 
Z, Andreeff M. CXCR4 expression and biologic activity in 
acute myeloid leukemia are dependent on oxygen partial 
pressure. Blood 2009;113:1504-12.
90.  Ayala F, Dewar R, Kieran M, Kalluri R. Contribution of bone 
microenvironment to leukemogenesis and leukemia progres-
sion. Leukemia 2009;23:2233-41.
91.  Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova 
O, Levis M, Rubin JB, Negrin RR, Estey EH, Konoplev S, 
Andreeff M, et al. Targeting the leukemia microenvironment 
by CXCR4 inhibition overcomes resistance to kinase inhibi-
tors and chemotherapy in AML. Blood 2009;113:6215-24.
92.  Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, 
Fujimi A, Akiyama T, Kuroda H, Kawano Y, Kobune M, 
Kato J, Hirayama Y, et al. Interaction between leukemic-cell 
VLA-4 and stromal fibronectin is a decisive factor for mini-
mal residual disease of acute myelogenous leukemia. Nat 
Med 2003;9:1158-65.
93.  Matsunaga T, Fukai F, Miura S, Nakane Y, Owaki T, Kodama 
H, Tanaka M, Nagaya T, Takimoto R, Takayama T, Niitsu Y. 
Combination therapy of an anticancer drug with the FNIII14 
peptide of fibronectin effectively overcomes cell adhesion-
mediated drug resistance of acute myelogenous leukemia. 
Leukemia 2008;22:353-60.
94.  Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W, 
Mills GB, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M. 
Activation of integrin-linked kinase is a critical prosurvival 
pathway induced in leukemic cells by bone marrow-derived 
stromal cells. Cancer Res 2007;67:684-94.
95.  McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray 
V, Wederell ED, Bally MB, Foster LJ, Dedhar S. Rictor and 
integrin-linked kinase interact and regulate Akt phosphoryla-
tion and cancer cell survival. Cancer Res 2008;68:1618-24.
96.  Bousquet M, Recher C, Queleen C, Demur C, Payrastre B, 
Brousset P. Assessment of somatic mutations in phosphati-
dylinositol 3-kinase gene in human lymphoma and acute leu-
kaemia. Br J Haematol 2005;131:411-3.
97.  Tibes R, Kornblau SM, Qiu Y, Mousses SM, Robbins C, 
Moses T, Carpten JD. PI3K/AKT pathway activation in acute 
myeloid leukaemias is not associated with AKT1 pleckstrin 
homology domain mutation. Br J Haematol 2008;140:344-7.
98.  Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phos-
phorylation of the PTEN tail regulates protein stability and 
function. Mol Cell Biol 2000;20:5010-8.
99.  Cheong JW, Eom JI, Maeng HY, Lee ST, Hahn JS, Ko YW, 
Min YH. Phosphatase and tensin homologue phosphorylation 
in the C-terminal regulatory domain is frequently observed 
in acute myeloid leukaemia and associated with poor clinical 
outcome. Br J Haematol 2003;122:454-6.
100. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, 
Wu H, Morrison SJ. Pten dependence distinguishes haema-
topoietic stem cells from leukaemia-initiating cells. Nature 
2006;441:475-82.
101. Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT, 
Haug JS, Rupp D, Porter-Westpfahl KS, Wiedemann LM, 
Wu H, Li L. PTEN maintains haematopoietic stem cells 
and acts in lineage choice and leukaemia prevention. Nature 
2006;441:518-22.
102. Chow S, Minden MD, Hedley DW. Constitutive phosphory-
lation of the S6 ribosomal protein via mTOR and ERK sig-
naling in the peripheral blasts of acute leukemia patients. Exp 
Hematol 2006;34:1183-91.
103. Dos Santos C, Demur C, Bardet V, Prade-Houdellier N, 
Payrastre B, Recher C. A critical role for Lyn in acute myeloid 
leukemia. Blood 2008;111:2269-79.
104. Xu Z, Wang M, Wang L, Wang Y, Zhao X, Rao Q, Wang J. 
Aberrant expression of TSC2 gene in the newly diagnosed 
acute leukemia. Leuk Res 2009;33:891-7.
105. Xu Q, Thompson JE, Carroll M. mTOR regulates cell sur-
vival after etoposide treatment in primary AML cells. Blood 
2005;106:4261-8.
106. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso 
R, Driscoll PC, Woscholski R, Parker PJ, Waterfield MD. 
Synthesis and function of 3-phosphorylated inositol lipids. 
Annu Rev Biochem 2001;70:535-602.
107. Bozulic L, Surucu B, Hynx D, Hemmings BA. PKBalpha/
Akt1 acts downstream of DNA-PK in the DNA double-strand 
break response and promotes survival. Mol Cell 2008;30:203-
13.
108. Neri LM, Borgatti P, Tazzari PL, Bortul R, Cappellini A, 
Tabellini G, Bellacosa A, Capitani S, Martelli AM. The phos-
phoinositide 3-kinase/AKT1 pathway involvement in drug 
and all-trans-retinoic acid resistance of leukemia cells. Mol 
Cancer Res 2003;1:234-46.
109. Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, 
Oncotarget 2010; 1: 89-103www.impactjournals.com/oncotarget/
102
Milella M, Estrov Z, Mills GB, Andreeff M. Inhibition 
of phosphatidylinositol 3-kinase dephosphorylates BAD 
and promotes apoptosis in myeloid leukemias. Leukemia 
2004;18:267-75.
110.Garcia-Echeverria C, Sellers WR. Drug discovery approaches 
targeting the PI3K/Akt pathway in cancer. Oncogene 
2008;27:5511-26.
111. Ihle NT, Powis G. Take your PIK: phosphatidylinositol 
3-kinase inhibitors race through the clinic and toward cancer 
therapy. Mol Cancer Ther 2009;8:1-9.
112. Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, Pes-
kett E, Sancho S, Smith AJ, Withers DJ, Vanhaesebroeck B. 
Critical role for the p110alpha phosphoinositide-3-OH kinase 
in growth and metabolic regulation. Nature 2006;441:366-
70.
113 Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Golden-
berg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth 
B, Balla T, Weiss WA, et al. A pharmacological map of the 
PI3-K family defines a role for p110alpha in insulin signal-
ing. Cell 2006;125:733-47.
114. Fu L, Kim YA, Wang X, Wu X, Yue P, Lonial S, Khuri FR, 
Sun SY. Perifosine Inhibits Mammalian Target of Rapamycin 
Signaling through Facilitating Degradation of Major Compo-
nents in the mTOR Axis and Induces Autophagy. Cancer Res 
2009;69:8967-76.
115. van Blitterswijk WJ, Verheij M. Anticancer alkylphospholip-
ids: mechanisms of action, cellular sensitivity and resistance, 
and clinical prospects. Curr Pharm Des 2008;14:2061-74.
116. Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi 
AM, Evangelisti C, Ottaviani E, Martinelli G, Testoni N, 
McCubrey JA, Martelli AM. Proapoptotic activity and che-
mosensitizing effect of the novel Akt inhibitor perifosine in 
acute myelogenous leukemia cells. Leukemia 2008;22:147-
60.
117. Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, 
Spiegel S, Grant S. Coadministration of histone deacetylase 
inhibitors and perifosine synergistically induces apoptosis in 
human leukemia cells through Akt and ERK1/2 inactivation 
and the generation of ceramide and reactive oxygen species. 
Cancer Res 2005;65:2422-32.
118. Tazzari PL, Tabellini G, Ricci F, Papa V, Bortul R, Chiarini 
F, Evangelisti C, Martinelli G, Bontadini A, Cocco L, McCu-
brey JA, Martelli AM. Synergistic proapoptotic activity of 
recombinant TRAIL plus the Akt inhibitor Perifosine in acute 
myelogenous leukemia cells. Cancer Res 2008;68:9394-403.
119. Chiarini F, Del Sole M, Mongiorgi S, Gaboardi GC, Cappel-
lini A, Mantovani I, Follo MY, McCubrey JA, Martelli AM. 
The novel Akt inhibitor, perifosine, induces caspase-depen-
dent apoptosis and downregulates P-glycoprotein expression 
in multidrug-resistant human T-acute leukemia cells by a 
JNK-dependent mechanism. Leukemia 2008;22:1106-16.
120. Rahmani M, Anderson A, Habibi JR, Crabtree TR, Mayo M, 
Harada H, Ferreira-Gonzalez A, Dent P, Grant S. The BH3-
only protein Bim plays a critical role in leukemia cell death 
triggered by concomitant inhibition of the PI3K/Akt and 
MEK/ERK1/2 pathways. Blood 2009;114:4507-16.
121. Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell 
KM, Jones RE, Kahana JA, Kral AM, Leander K, Lee LL, 
Malinowski J, McAvoy EM, et al. Identification and char-
acterization of pleckstrin-homology-domain-dependent and 
isoenzyme-specific Akt inhibitors. Biochem J 2005;385:399-
408.
122. Fasolo A, Sessa C. mTOR inhibitors in the treatment of 
cancer. Expert Opin Investig Drugs 2008;17:1717-34.
123. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, 
Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi 
I, Kovacevic Z, Lesovoy V, et al. Temsirolimus, interferon 
alfa, or both for advanced renal-cell carcinoma. N Engl J Med 
2007;356:2271-81.
124. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the 
mTOR signaling network for cancer therapy. J Clin Oncol 
2009;27:2278-87.
125. Abraham RT, Gibbons JJ. The mammalian target of rapamy-
cin signaling pathway: twists and turns in the road to cancer 
therapy. Clin Cancer Res 2007;13:3109-14.
126. Leone M, Crowell KJ, Chen J, Jung D, Chiang GG, Sareth 
S, Abraham RT, Pellecchia M. The FRB domain of mTOR: 
NMR solution structure and inhibitor design. Biochemistry 
2006;45:10294-302.
127. Foster DA, Toschi A. Targeting mTOR with rapamycin: one 
dose does not fit all. Cell Cycle 2009;8:1026-9.
128. Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, 
Ellen Jackson C, Giles FJ, Sabatini DM, Andreeff M, Kono-
pleva M. Rapamycin derivatives reduce mTORC2 signaling 
and inhibit AKT activation in AML. Blood 2007;109:3509-
12.
129. Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos 
Santos C, Mas VM, Benzaquen D, Laurent G, Huguet F, 
Payrastre B. Antileukemic activity of rapamycin in acute 
myeloid leukemia. Blood 2005;105:2527-34.
130. Nishioka C, Ikezoe T, Yang J, Gery S, Koeffler HP, Yokoyama 
A. Inhibition of mammalian target of rapamycin signaling 
potentiates the effects of all-trans retinoic acid to induce 
growth arrest and differentiation of human acute myelog-
enous leukemia cells. Int J Cancer 2009;125:1710-20.
131. Nishioka C, Ikezoe T, Yang J, Koeffler HP, Yokoyama A. 
Blockade of mTOR signaling potentiates the ability of his-
tone deacetylase inhibitor to induce growth arrest and dif-
ferentiation of acute myelogenous leukemia cells. Leukemia 
2008;22:2159-68.
132. Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, 
Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, 
O'Brien S, Andreeff M, et al. Phase I/II study of the mam-
malian target of rapamycin inhibitor everolimus (RAD001) 
in patients with relapsed or refractory hematologic malignan-
cies. Clin Cancer Res 2006;12:5165-73.
133. Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, 
Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ. A 
phase 2 clinical trial of deforolimus (AP23573, MK-8669), 
a novel mammalian target of rapamycin inhibitor, in patients 
with relapsed or refractory hematologic malignancies. Clin 
Cancer Res 2008;14:2756-62.
134. Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster 
SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta 
SD, Hexner EO, et al. A phase I study of the mammalian 
target of rapamycin inhibitor sirolimus and MEC chemother-
apy in relapsed and refractory acute myelogenous leukemia. 
Oncotarget 2010; 1: 89-103www.impactjournals.com/oncotarget/
103
Clin Cancer Res 2009;15:6732-9.
135. Teachey DT, Grupp SA, Brown VI. Mammalian target of 
rapamycin inhibitors and their potential role in therapy in 
leukaemia and other haematological malignancies. Br J Hae-
matol 2009;145:569-80.
136. Karp JE, Flatten K, Feldman EJ, Greer JM, Loegering DA, 
Ricklis RM, Morris LE, Ritchie E, Smith BD, Ironside V, Tal-
bott T, Roboz G, et al. Active oral regimen for elderly adults 
with newly diagnosed acute myelogenous leukemia: a pre-
clinical and phase 1 trial of the farnesyltransferase inhibitor 
tipifarnib (R115777, Zarnestra) combined with etoposide. 
Blood 2009;113:4841-52.
137. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Rug-
gero D, Shokat KM. Active-site inhibitors of mTOR target 
rapamycin-resistant outputs of mTORC1 and mTORC2. 
PLoS Biol 2009;7:e38.
138. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, 
Reichling LJ, Sim T, Sabatini DM, Gray NS. An ATP-com-
petitive mammalian target of rapamycin inhibitor reveals 
rapamycin-resistant functions of mTORC1. J Biol Chem 
2009;284:8023-32.
139. Garcia-Martinez JM, Moran J, Clarke RG, Gray A, Cosulich 
SC, Chresta CM, Alessi DR. Ku-0063794 is a specific inhibi-
tor of the mammalian target of rapamycin (mTOR). Biochem 
J 2009;421:29-42.
140. Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim 
J, Verheijen J, Curran K, Malwitz DJ, Cole DC, Ellingboe J, 
et al. Biochemical, cellular, and in vivo activity of novel ATP-
competitive and selective inhibitors of the mammalian target 
of rapamycin. Cancer Res 2009;69:6232-40.
141. Nowak P, Cole DC, Brooijmans N, Bursavich MG, Curran 
KJ, Ellingboe JW, Gibbons JJ, Hollander I, Hu Y, Kaplan J, 
Malwitz DJ, Toral-Barza L, et al. Discovery of potent and 
selective inhibitors of the mammalian target of rapamycin 
(mTOR) kinase. J Med Chem 2009;52:7081-9.
142. Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Wil-
lems L, Uzunov M, Ifrah N, Dreyfus F, Lacombe C, Mayeux 
P, Bouscary D. Protein synthesis is resistant to rapamycin and 
constitutes a promising therapeutic target in acute myeloid 
leukemia. Blood 2009;114:1618-27.
143. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, 
Stokoe D, Shokat KM, Weiss WA. A dual PI3 kinase/mTOR 
inhibitor reveals emergent efficacy in glioma. Cancer Cell 
2006;9:341-9.
144. Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix 
S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, Bjerke LM, 
Kelland L, et al. Pharmacologic characterization of a potent 
inhibitor of class I phosphatidylinositide 3-kinases. Cancer 
Res 2007;67:5840-50.
145. Steelman LS, McCubrey JA. Intriguing novel abilities of 
Nutlin-3A: induction of cellular quiescence as opposed to 
cellular senescence--implications for chemotherapy. Cell 
Cycle 2009;8:3634-5.
146. Korotchkina LG, Demidenko ZN, Gudkov AV, Blagosklonny 
MV. Cellular quiescence caused by the Mdm2 inhibitor nut-
lin-3A. Cell Cycle 2009;8:3777-81.
147. Kojima K, Shimanuki M, Shikami M, Samudio IJ, Ruvolo V, 
Corn P, Hanaoka N, Konopleva M, Andreeff M, Nakakuma 
H. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 
induction by Mdm2 inhibition but enhances p53-mediated 
mitochondrial apoptosis in p53 wild-type AML. Leukemia 
2008;22:1728-36.
148. Park S, Chapuis N, Bardet V, Tamburini J, Gallay N, Wil-
lems L, Knight ZA, Shokat KM, Azar N, Viguie F, Ifrah N, 
Dreyfus F, et al. PI-103, a dual inhibitor of Class IA phospha-
tidylinositide 3-kinase and mTOR, has antileukemic activity 
in AML. Leukemia 2008;22:1698-706.
149. Shor B, Gibbons JJ, Abraham RT, Yu K. Targeting mTOR 
globally in cancer: Thinking beyond rapamycin. Cell Cycle 
2009;8:3831-7.
150. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, 
Workman P. Targeting the PI3K-AKT-mTOR pathway: prog-
ress, pitfalls, and promises. Curr Opin Pharmacol 2008;8:393-
412.
151. Engelman JA. Targeting PI3K signalling in cancer: opportuni-
ties, challenges and limitations. Nat Rev Cancer 2009;9:550-
62.
152. Tazzari PL, Cappellini A, Grafone T, Mantovani I, Ricci 
F, Billi AM, Ottaviani E, Conte R, Martinelli G, Martelli 
AM. Detection of serine 473 phosphorylated Akt in acute 
myeloid leukaemia blasts by flow cytometry. Br J Haematol 
2004;126:675-81.
153. Bardet V, Tamburini J, Ifrah N, Dreyfus F, Mayeux P, Bous-
cary D, Lacombe C. Single cell analysis of phosphoinositide 
3-kinase/Akt and ERK activation in acute myeloid leukemia 
by flow cytometry. Haematologica 2006;91:757-64.
154. Gora-Tybor J, Robak T. Targeted drugs in chronic myeloid 
leukemia. Curr Med Chem 2008;15:3036-51.
155. Hambley TW, Hait WN. Is anticancer drug development 
heading in the right direction? Cancer Res 2009;69:1259-62.
156. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 
2008;68:3077-80; discussion 80.
Oncotarget 2010; 1: 89-103www.impactjournals.com/oncotarget/
